Our results showed that both compounds, CA and Met, had the potential to inhibit mesenchymal phenotype induced with TGF-β1 in cervical cancer cells, but each drug acted via various proteins in the particular cell line. The gene discussed is TGFB1; the disease is cervical carcinoma.